| Net revenue genomics | 451.75a | 363.02a | 197.98a |
| Data and services | 241.65a | 168.8a | 122.68a |
| Total net revenue | 693.4a | 531.82a | 320.67a |
| Cost and operating expenses | — | — | — |
| Cost of revenues, genomics | -243.47a | -189.17a | -150.26a |
| Cost of revenues, data and services | -68.82a | -56.48a | -40.23a |
| Technology research and development | -167.52a | -95.16a | -79.09a |
| Research and development | -149.33a | -90.34a | -83.16a |
| Selling, general and administrative | -755.35a | -296.76a | -233.38a |
| Total cost and operating expenses | -1,384.48a | -727.91a | -586.11a |
| Loss from operations | -691.08a | -196.08a | -265.44a |
| Interest income | 11.08a | 7.6a | 3.03a |
| Interest expense | -53.65a | -46.87a | -21.89a |
| Other income (expense), net | 32.34a | 21.82a | -4.85a |
| Loss before provision for income taxes | -701.32a | -213.53a | -289.15a |
| Provision for income taxes | -0.27a | -0.29a | -0.07a |
| Losses from equity method investments | -4.23a | -0.3a | -0.6a |
| Net loss | -705.81a | -214.12a | -289.81a |
| Accretion of convertible preferred stock to redemption value | | -4.34a | -0.3a |
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | -39.35a | -44.5a | -40.98a |
| Cumulative undeclared dividends on Series C preferred shares | -1.17a | -3.01a | -2.84a |
| Net loss attributable to common shareholders, basic and diluted | -746.33a | -265.96a | -333.93a |